The mechanism is understood. The infrastructure is in place. The preliminary evidence is positive. What is missing is the controlled trial that would make IMIG accessible to children with immune-dysregulated autism worldwide.
A well-defined subpopulation of children with autism spectrum disorder has documented immune dysregulation — elevated pro-inflammatory cytokines, IgG subclass deficiencies, or autoantibodies to brain proteins. In these children, neuroinflammation is not a secondary feature of autism. It is an active, measurable driver that can be targeted directly.
Intravenous immunoglobulin (IVIG) has been studied in autism for two decades. A 2021 meta-analysis of 27 publications showed large effect sizes for behavioural outcomes in this subpopulation — effect sizes exceeding those of most approved pharmacological treatments. But IVIG costs $10,000–$25,000 per infusion, requires an infusion centre and IV access, and produces oscillating serum IgG levels that may work against the sustained inflammatory suppression the cascade biology requires.
Intramuscular immunoglobulin (IMIG) is a different pharmacokinetic profile. A small-volume monthly injection costing approximately $50–$80 per treatment produces a slower, sustained IgG elevation — a steady-state that may be mechanistically preferable for cascade recovery. The first published IMIG case report in ASD and PANS (Fourie & Armstrong, Medical Research Archives, 2024) demonstrated meaningful clinical signal. In the PANS group, where the autoimmune mechanism is well-characterised, the mean improvement score was 4.4 out of 5. The principal investigator has since expanded the programme to more than forty patients.
No randomised controlled trial of IMIG in autism has been conducted. This is the gap this initiative exists to close.
Think of IMIG as doing for immune dysregulation what FMT does for the microbiome — restoring a biological deficit using established, human-derived material.
Without the risk.
The clinical, manufacturing, and regulatory infrastructure to conduct a well-designed controlled pilot study already exists. What is currently absent is the funding to initiate it.
Autism affects an estimated 1 in 36 children in the United States and rising proportions globally. Despite decades of research, no treatment addresses the underlying biological mechanisms for any defined subpopulation. Approved pharmacological interventions target behavioural symptoms only — they do not address the immune and metabolic drivers that the evidence increasingly implicates.
IMIG is not a treatment for all autism. It is a candidate treatment for a biologically defined subgroup — children with measurable immune dysregulation, identifiable through standard clinical laboratory testing. The cascade framework's testing protocol provides an evidence-based pathway for identifying this population. The biomarker stratification that has been missing from most autism intervention trials is built into the trial design from the outset.
The Proposed IMIG for Autism Controlled Pilot Study represents a fraction of the cost of a failed late-stage pharmaceutical programme — and produces data that could support regulatory approval for the first biologically targeted, affordable treatment for a defined ASD subpopulation. At $50–$80 per treatment, IMIG is accessible in resource-limited settings globally. No such approved treatment currently exists anywhere in the world.
This initiative site presents the complete scientific and clinical case across four dedicated pages. Each is written for a reader with scientific or clinical background — a foundation program officer, a medical affairs director, or a clinical researcher evaluating the opportunity.
For the foundational biology of autism framework that underpins this initiative — the full cascade model, testing strategy, and intervention logic — see the Biology of Autism suite at DecodingAutismNow.com.
Research context — not clinical guidance. This site presents published peer-reviewed research and ongoing clinical work in support of a proposed clinical trial. It does not constitute medical advice. IMIG for ASD is investigational and not approved for this indication in any jurisdiction. All clinical decisions require qualified medical and specialist oversight.